She has received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen and Sanofi-Aventis and Eli Lilly
MM.1S, RPMI-8226, NCI-H929 and OPM-2 were maintained in RPMI-1640 medium with 10% FBS
Oral bioavailability for Dihexa has been estimated at 4060% in animal models, substantially higher than most peptides which typically show less than 5% oral absorption due to first-pass metabolism and enzymatic degradation in the gastrointestinal tract
[64] ARQ197 (ArQule) is a promising selective inhibitor of MET, which entered a phase 2 clinical trial in 2008
In large doses, it can cause excessive body stimulation, restlessness, insomnia, increased blood pressure, nervousness, inability to concentrate, headaches, and nosebleeds [218,219]
Note on injection: These benefits are not established for injected GHK-Cu in humans no controlled clinical trials of systemic GHK-Cu have been completed [11]